News
-
-
PRESS RELEASE
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
Sanofi acquires Vigil Neuroscience to enhance neurology pipeline with an investigational medicine for Alzheimer's disease. The acquisition includes VG-3927, a small molecule TREM2 agonist -
-
-
PRESS RELEASE
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creating global consumer healthcare leader. Sanofi's sale of a 50.0% stake to CD&R marks a strategic move with total net cash proceeds of around €10 billion -
-
PRESS RELEASE
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 study in NEJM shows delayed disability progression in multiple sclerosis. Potential first therapy targeting immunologic drivers. US priority review ongoing -
-
PRESS RELEASE
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases -
